AbbVie – a missed opportunity?

AbbVie is one of the cheapest companies in The Dividend Aristocrats spectrum when it comes to P/E and is offering one of the highest dividend yields. This is why company seems interesting to me. My current investable level is at $55, but when share price was at that...

AbbVie – time to buy is coming?

AbbVie share price has come to my investable level – it doesn’t mean that I am closing my eyes and buying immediately. It means that it is a high time to have another look at company. I wrote in my last note: From financial perspective company is paying a decent yield...

AbbVie – how is business going?

When I went through my valuation spreadsheet today I came across on AbbVie as one of the cheapest (on P/E ratio) and high dividend yielding company. I looked at company at the beginning of the year (see more) and I found company rather risky. Year to date company is...

AbbVie – growth story to be continued?

AbbVie is a spin-off (2013) of the global pharma research and development division of Abbott Laboratories. What’s interesting current market cap of AbbVie is higher than remaining business of Abbott Labs. Currently company discovers, develops and markets both...